Akebia Therapeutics (AKBA) Receivables - Net (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Receivables - Net data on file, last reported at $62.5 million in Q1 2026.

• On a quarterly basis, Receivables - Net rose 1.62% year-over-year to $62.5 million in Q1 2026; TTM through Mar 2026 was $62.5 million, a 1.62% increase from a year earlier, with the FY2025 full-year figure at $47.0 million, up 36.85% from the prior year.
• Receivables - Net for Q1 2026 stood at $62.5 million, up from $47.0 million in the prior quarter.
• Over the last five years, Receivables - Net for AKBA reached as high as $82.0 million in Q2 2022 and fell as low as $18.7 million in Q1 2023.
• Historically, Receivables - Net has averaged $43.8 million across 5 years, with a median of $39.3 million in 2023.
• Across the five-year window, Receivables - Net soared 5654.86% in 2022 and sank 76.13% in 2023, its largest moves.
• Year by year, Receivables - Net stood at $40.3 million in 2022, then dropped by 2.47% to $39.3 million in 2023, then fell by 12.53% to $34.4 million in 2024, then jumped by 36.85% to $47.0 million in 2025, then jumped by 32.97% to $62.5 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $62.5 million in Q1 2026, $47.0 million in Q4 2025, and $66.2 million in Q3 2025.